Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6526 | 0.84 | ADRA2A (0.66) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL6056 | 0.81 | POLB (0.59) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL6021 | 0.81 | ADRA2A (0.65) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL6399 | 0.79 | ADRA2A (0.51) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL6475 | 0.79 | ADRA2A (0.62) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL5992 | 0.79 | POLB (0.60) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL6400 | 0.76 | POLB (0.87) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL5627 | 0.75 | ADRA2A (0.50) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL6690739 | 0.73 | ADRA2A (0.54) | POLBADRA2AADRA2BADRA2CKMT2A | |
| SCHEMBL10857050 | 0.73 | ADRA2A (0.54) | POLBADRA2AADRA2BADRA2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491017-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-08-27 | — | — | EP | claimed |
| US-20120238615-A1 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2012-09-20 | — | — | US | claimed |
| EP-2491017-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011050030-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| EP-2491017-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20120238615-A1 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2491017-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050030-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238615-A1 | Alpha adrenergic receptor modulators | ADRA2C, ADRB2, ADRB1 | POLB 2372/4885ADRA2A 4/4885ADRA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.